8-K: REMSleep Names New CEO, Reconstitutes Board After Founder's Passing

REMSleep Holdings appoints Jeffrey Marshall as CEO and reconstitutes its board following the passing of founder Thomas Wood, outlining new leadership's compensation and financial controls.

Summary

• REMSleep Holdings, Inc. reported the passing of its founder, Chairman, and Chief Executive Officer, Thomas Wood, on February 26, 2026.
• Thomas Wood was instrumental in conceiving and developing the DeltaWave Nasal Pillow System and securing its FDA clearance.
• Effective March 2, 2026, Anita Michaels, COO and sister of Thomas Wood, who inherited his ownership interest including super voting preferred shares, was elected Chairman of the Board.
• Jeffrey Marshall was appointed Chief Executive Officer and a Director, effective March 2, 2026.
• Alexander Johnson was also appointed as a Director, effective March 2, 2026, bringing corporate consulting and capital markets advisory experience.
• Jeffrey Marshall's Executive Employment Agreement, effective February 2, 2026, sets an initial annual base salary of $60,000, increasing to $120,000 upon the company raising at least $250,000 in gross proceeds from a Regulation A offering or subsequent financing.
• Marshall is eligible for performance-based equity compensation of up to 7% of the company's fully diluted capitalization, contingent on achieving specific funding and revenue milestones.
• An initial grant of 3% equity is contingent on raising at least $1,000,000 in gross proceeds from a Regulation A offering or subsequent financing.
• During an interim period, Anita Michaels retains oversight and approval authority over all financial matters, requiring Marshall to obtain her prior approval for any financial commitments or expenditures.
• Anita Michaels also reserves the unilateral right to terminate Marshall's employment within 30 days of the effective date or if the company fails to raise $250,000 in funding in 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the appointment of new leadership and a structured compensation plan are positive steps, the significant financial hurdles for full compensation and the interim financial controls on the CEO introduce considerable risk and uncertainty regarding the company's immediate operational flexibility and funding success.

Positives

• The company has quickly established a new leadership structure following the founder's passing, ensuring continuity in governance.
• Jeffrey Marshall brings extensive industry experience in sales, marketing, business development, and corporate leadership to the CEO role.
• The compensation package for the new CEO includes significant performance-based equity incentives (up to 7% of fully diluted capitalization), aligning his interests with shareholder value creation.
• The DeltaWave Nasal Pillow System has already achieved FDA clearance, indicating product readiness for commercialization.
• The Board is committed to honoring the founder's legacy through execution, suggesting a continued focus on the company's core product and mission.

Negatives

• The company experienced the significant loss of its founder, Chairman, and CEO, Thomas Wood, who was central to its product development and FDA clearance.
• The initial annual base salary for the new CEO, Jeffrey Marshall, is $60,000, which is considerably low for a CEO of a publicly traded company, even an emerging growth one.
• The new CEO's financial authority is severely restricted during an interim period, requiring prior approval from Chairman Anita Michaels for all financial decisions, which could hinder operational agility.
• The increase in the CEO's base salary and the granting of equity compensation are contingent on the company successfully raising substantial capital ($250,000 for salary increase, $1,000,000 for initial equity grant).
• Chairman Anita Michaels retains a unilateral right to terminate the CEO's employment within 30 days of the effective date or if the company fails to raise $250,000 in 2026, creating significant job insecurity for the new CEO.

Risks

• The company's ability to increase the CEO's salary and grant equity compensation is highly dependent on successful capital raising efforts through a Regulation A offering or subsequent financing, which is not guaranteed.
• The interim financial controls, where Chairman Anita Michaels maintains oversight and approval authority over all financial matters, could potentially slow down decision-making and limit the new CEO's operational autonomy.
• The unilateral right of Anita Michaels to terminate the CEO's employment within 30 days of the effective date or if funding targets are not met introduces significant uncertainty regarding leadership stability.
• The loss of founder Thomas Wood, who personally championed the FDA clearance process and built the company, could impact institutional knowledge and strategic direction.
• The company operates in the competitive medical device industry, and successful commercialization of the DeltaWave Nasal Pillow System will require effective execution and market penetration.

Future Outlook

The Company anticipates scaling its commercial operations under new executive leadership, with a focus on capital raising efforts through a Regulation A offering or subsequent financing to support growth and enable full CEO compensation and equity incentives. Product distribution is also a key forward-looking activity.

Management Comments

• Thomas Wood conceived and developed the DeltaWave Nasal Pillow System, personally championed the Company’s FDA clearance process through more than four years of regulatory work, and built REMSleep from the ground up.
• His contributions to the Company and to the broader field of sleep medicine are lasting, and the Board is committed to honoring that legacy through execution.
• Anita Michaels has maintained financial oversight of the Company and will continue to do so as the Company scales its commercial operations under new executive leadership.
• Executive acknowledges and agrees that this interim financial oversight arrangement is appropriate given the transition period and the Company’s financial circumstances, and that this arrangement does not diminish Executive’s title or authority as Chief Executive Officer with respect to non-financial matters.

Industry Context

StockSavvy.ai notes that the medical device industry, particularly in sleep therapy, is competitive and requires significant capital for commercialization and market penetration. The transition of leadership following the passing of a founder is a critical juncture, often presenting both challenges in maintaining continuity and opportunities for fresh strategic direction. The emphasis on FDA clearance and commercial readiness positions REMSleep to potentially capitalize on market demand for its DeltaWave Nasal Pillow System, assuming successful capital raises and effective execution by the new leadership team.

Comparison to Industry Standards

• The initial CEO salary of $60,000 is significantly below industry standards for a publicly traded medical device company, even an emerging growth one, reflecting the company's early commercial stage and financial constraints. For instance, CEOs of comparable small-cap medical device companies typically command base salaries ranging from $250,000 to $500,000 or more.
• The potential increase to $120,000 upon a $250,000 capital raise is still modest but indicates a structured path towards more competitive compensation as the company secures funding.
• The equity compensation package of up to 7% of fully diluted capitalization, tied to significant funding and revenue milestones, is a common incentive structure in early-stage public companies, aligning CEO interests with shareholder value creation. This is comparable to equity grants seen in biotech or med-tech startups where founders or key executives often hold 5-15% of the company.
• The interim financial oversight by the Chairman (Anita Michaels) is an unusual but understandable measure during a critical leadership transition, especially given her majority shareholder status and familial relationship to the founder. This level of direct financial control is not standard for a newly appointed CEO in a typical public company setting, where the CEO usually has broader operational and financial autonomy within board-approved budgets.

Management Changes

Corporate Governance

Related Party Transactions

• Anita Michaels, COO and sister of the deceased founder Thomas Wood, inherited his ownership interest, including super voting preferred shares, and was subsequently elected Chairman of the Board.
• Alexander Johnson, a newly appointed director, previously consulted for REMSleep Holdings, Inc. in connection with its capital formation strategy, investor communications, and corporate governance.
• The Executive Employment Agreement for Jeffrey Marshall includes an interim transition arrangement providing the Chairman (Anita Michaels) certain rights during the initial period of employment, including oversight and approval authority over all financial matters.

Stakeholder Impact

• **Shareholders:** The passing of the founder creates uncertainty but the appointment of new leadership and a reconstituted board aims to provide stability. The structured equity compensation for the new CEO aligns his incentives with shareholder value creation, contingent on successful capital raises and revenue growth. However, the significant control retained by Anita Michaels (majority shareholder, super voting shares, interim financial oversight) could be a point of concern for minority shareholders regarding independent governance.
• **Employees:** The leadership transition may bring changes in strategic direction and operational focus. The commitment to commercialization could lead to future growth opportunities.
• **Customers:** The company's focus on scaling commercial operations for the DeltaWave Nasal Pillow System suggests continued product availability and potential expansion, which is positive for existing and prospective customers.
• **Creditors/Suppliers:** The company's financial health and ability to meet obligations are tied to successful capital raises. The interim financial controls by the Chairman could impact payment processes or contract approvals in the short term.

Next Steps

• Establishment of an Incentive Stock Option Plan following a Regulation A offering that raises at least $1,000,000.
• Scaling of commercial operations under the new executive leadership.
• Jeffrey Marshall to spearhead the development and structuring of the ISO Plan.
• Anita Michaels to determine, in her sole discretion, the transition of full financial authority to Jeffrey Marshall.
• Company to pursue a Regulation A offering or subsequent financing to meet funding thresholds for CEO compensation and equity.

Key Dates

Recommendation

The filing presents a mixed bag of significant changes. The passing of the founder is a major loss, but the company has moved quickly to reconstitute its board and appoint a new CEO with relevant industry experience. The structured compensation plan, including substantial equity incentives tied to funding and revenue milestones, aligns the CEO's interests with long-term growth. However, the company's immediate financial constraints, evidenced by the low initial CEO salary and the critical dependence on future capital raises, introduce considerable risk. The interim financial controls on the CEO and the Chairman's unilateral termination rights also create uncertainty regarding operational autonomy and leadership stability. Investors should hold to observe the new leadership's ability to secure necessary funding, execute commercialization plans, and navigate the unique governance structure before making further investment decisions.

Keywords

REMSleep Holdings, RMSL, CEO appointment, Board of Directors, corporate governance, executive compensation, incentive stock options, capital raise, Regulation A, medical device, sleep medicine, leadership transition